These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19602215)

  • 1. Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany.
    Gandjour A; Weyler EJ
    Value Health; 2008 Dec; 11(7):1088-95. PubMed ID: 19602215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model.
    Stollenwerk B; Bartmus T; Klug F; Stock S; Müller D
    Osteoporos Int; 2015 Apr; 26(4):1367-79. PubMed ID: 25572047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents.
    Singh S; Sun H; Anis AH
    J Rheumatol; 2004 Aug; 31(8):1607-13. PubMed ID: 15290742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-benefit analysis of external hip protectors in the nursing home setting.
    Honkanen LA; Schackman BR; Mushlin AI; Lachs MS
    J Am Geriatr Soc; 2005 Feb; 53(2):190-7. PubMed ID: 15673340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of hip protectors in frail institutionalized elderly.
    van Schoor NM; de Bruyne MC; van der Roer N; Lommerse E; van Tulder MW; Bouter LM; Lips P
    Osteoporos Int; 2004 Dec; 15(12):964-9. PubMed ID: 15103454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic analysis of external hip protector use in ambulatory nursing facility residents.
    Colón-Emeric CS; Datta SK; Matchar DB
    Age Ageing; 2003 Jan; 32(1):47-52. PubMed ID: 12540348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased use of hip protectors in nursing homes: economic analysis of a cluster randomized, controlled trial.
    Meyer G; Wegscheider K; Kersten JF; Icks A; Mühlhauser I
    J Am Geriatr Soc; 2005 Dec; 53(12):2153-8. PubMed ID: 16398901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Socioeconomic burden of hip fractures in Germany].
    Weyler EJ; Gandjour A
    Gesundheitswesen; 2007 Nov; 69(11):601-6. PubMed ID: 18080931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes.
    Müller D; Borsi L; Stracke C; Stock S; Stollenwerk B
    Eur J Health Econ; 2015 Jun; 16(5):517-27. PubMed ID: 24818587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could a policy of provision of hip protectors to elderly nursing home residents result in cost savings in acute hip fracture care? The case of Ontario, Canada.
    Sawka AM; Gafni A; Boulos P; Beattie K; Papaioannou A; Cranney A; Hanley DA; Adachi JD; Cheung A; Papadimitropoulos EA; Thabane L
    Osteoporos Int; 2007 Jun; 18(6):819-27. PubMed ID: 17221294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
    Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
    Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and effectiveness of hip protectors among the elderly.
    Segui-Gomez M; Keuffel E; Frick KD
    Int J Technol Assess Health Care; 2002; 18(1):55-66. PubMed ID: 11987442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
    Honkanen LA; Mushlin AI; Lachs M; Schackman BR
    J Am Geriatr Soc; 2006 Nov; 54(11):1658-65. PubMed ID: 17087691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery for hip fracture yields societal benefits that exceed the direct medical costs.
    Gu Q; Koenig L; Mather RC; Tongue J
    Clin Orthop Relat Res; 2014 Nov; 472(11):3536-46. PubMed ID: 25091223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial.
    Kiel DP; Magaziner J; Zimmerman S; Ball L; Barton BA; Brown KM; Stone JP; Dewkett D; Birge SJ
    JAMA; 2007 Jul; 298(4):413-22. PubMed ID: 17652295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of type of hip protector and resident characteristics on adherence to use of hip protectors in nursing and residential homes--an exploratory study.
    O'Halloran PD; Murray LJ; Cran GW; Dunlop L; Kernohan G; Beringer TR
    Int J Nurs Stud; 2005 May; 42(4):387-97. PubMed ID: 15847901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Utilization of external hip protectors in frail elderly residents of nursing homes].
    Mendelson G; Ben-Israel J
    Harefuah; 2005 Feb; 144(2):112-4, 150. PubMed ID: 16128016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic modeling on cost-effectiveness of hip protectors in institutionalized older people based on contentious interpretation of original effectiveness data.
    Oliver D; Connelly J; Allain T
    J Am Geriatr Soc; 2005 Dec; 53(12):2241-2. PubMed ID: 16398924
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.